$98.540
+1.941 (+1.97%)Al cierre
Noticias de ATGE
Eventos de ATGE
Adtalem Maintains FY 2026 Revenue Guidance at $1.9B-$1.94B
EPS consensus $7.84. Adtalem maintained its revenue guidance for fiscal year 2026, with revenue in the range of $1.9B-$1.94B, approximately 6% to 8.5% growth year-over-year, consensus $1.93B
Adtalem Global Education Q2 Revenue $503.385M Beats Expectations
Reports Q2 revenue $503.385M, consensus $488.72M. "As America's largest healthcare educator, we are uniquely positioned to address the growing healthcare workforce gaps at scale. Our second quarter results - our tenth consecutive quarter of enrollment growth, which was up 6.3% to 97,000 students - demonstrate our ability to meet this challenge head on," said Steve Beard, chairman and chief executive officer, Adtalem Global Education. "We are at the forefront, creating a future where barriers to education are removed and where students graduate with AI-fluency. We took significant steps forward this quarter further collaborating with health system partners, expanding our reach, and embedding AI within our programs. As we train more healthcare providers than ever before, we are also delivering strong shareholder returns and leveraged our financial strength to return $165 million of capital back to our owners."
Adtalem Global Education Stock Rises 6.5% to $98.92
Adtalem Global Education is up 6.5%, or $6.04 to $98.92.
Adtalem Completes $150M Share Repurchase and Secures $750M New Buyback Authorization
Adtalem Global Education announced the completion of its $150M share repurchase program, under which the company repurchased approximately 1.6M shares, and a new $750M share repurchase authorization approved by the board of directors through December 2028. The new three-year authorization underscores management and the board's conviction in Adtalem's strategic direction, strong financial position, and ability to generate substantial cash flow while continuing to invest in growth initiatives.
Adtalem confirms FY26 adjusted EPS forecast of $7.60-$7.90, aligning with consensus of $7.81
Reaffirms FY25 revenue view $1.900M-$1.940M, consensus $1.93B.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.